
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services, with expertise in whole-exome and whole-genome testing, particularly in children. The company's shift to focus on pediatric and rare-disease diagnostics positions it to capitalize on the growing demand for precision medicine and genetic diagnoses. With the recent acquisition of Fabric Genomics, GeneDx can expand its reach and potentially enter international markets, making it a strong and diversified player in the genomics industry.
Bears say
GeneDx Holdings is facing significant headwinds due to missed revenue expectations and decreased gross margin. The company's reliance on whole exome and genome sequencing, while potentially revolutionary, presents risks from reimbursement challenges and potential reluctance from geneticists to move from targeted gene panels. GeneDx is also facing pressure from competition and pricing in various segments, including in its core base NIPT market. Despite these challenges, the company's focus on rare pediatric diseases and potential for data monetization opportunities may provide future growth opportunities, but the near-term outlook is uncertain.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares